Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: Mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs

Cell Death and Differentiation

Volumn 21, Issue 8, 2014, Pages 1240-1249

  Bunjobpol, W ^a   Dulloo, I ^a   Igarashi, K ^b   Concin, N ^c   Matsuo, K ^d   Sabapathy, K ^a,e,f  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b CHIBA UNIVERSITY   (Japan)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KEIO UNIVERSITY   (Japan)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLPOLYAMINE OXIDASE; ANTINEOPLASTIC AGENT; ANTIZYME; CISPLATIN; CYTOTOXIC AGENT; DELTA NP73 PROTEIN; DOXORUBICIN; OXIDOREDUCTASE; POLYAMINE; PROTEIN; PROTEIN C JUN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; POLYAMINE OXIDASE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; BINDING SITE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; DRUG RESISTANCE; ENZYMOLOGY; HCT116 CELL LINE; LUNG NEOPLASMS; METABOLISM; MOUSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HUMANS; LUNG NEOPLASMS; MICE; NUCLEAR PROTEINS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84905039245     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.41     Document Type: Article

References (48)

1. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-615; Review.
2. Jost CA, Marin MC, Kaelin Jr WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997; 389: 191-194.
3. Stiewe T, Theseling CC, Pützer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002; 277: 14177-14185.
4. Liu G, Nozell S, Xiao H, Chen X. DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 2004; 24: 487-501.
5. Toh WH, Logette E, Corcos L, Sabapathy K. TAp73beta and DNp73beta activate the expression of the pro-survival caspase-2S. Nucleic Acids Res 2008; 36: 4498-4509.
6. Tanaka Y, Kameoka M, Itaya A, Ota K, Yoshihara K. Regulation of HSF1-responsive gene expression by N-terminal truncated form of p73alpha. Biochem Biophys Res Commun 2004; 317: 865-872.
7. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010; 24: 549-560.
8. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196: 765-780.
9. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64: 2449-2460.
10. Buhlmann S, Pützer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 2008; 1785: 207-216.
11. Lin KW, Nam SY, Toh WH, Dulloo I, Sabapathy K. Multiple stress signals induce p73beta accumulation. Neoplasia 2004; 6: 546-557.
12. Di C, Yang L, Zhang H, Ma X, Zhang X, Sun C et al. Mechanisms, function and clinical applications of DNp73. Cell Cycle 2013; 12: 1861-1867.
13. Stiewe T, Pützer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002; 9: 237-245.
14. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ 2004; 11: 685-687.
15. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005; 24: 836-848.
16. Tsai KK, Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 2003; 63: 3418-3424.
17. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 1545-1557.
18. Asher G, Tsvetkov P, Kahana C, Shaul Y.A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19: 316-321.
19. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene 2003; 22: 1678-1687.
20. Dulloo I, Gopalan G, Melino G, Sabapathy K. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA 2010; 107: 4902-4907.
21. Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF et al. Autoregulatory frameshifting in decoding mammalian ornithinedecarboxylase antizyme. Cell 1995; 80: 51-60.
22. Casero Jr RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007; 6: 373-390.
23. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400.
24. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-5973.
25. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20: 2438-2452.
26. Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 2002; 22: 4952-4964.
27. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868.
28. Coffino P. Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2001; 2: 188-194.
29. Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 1999; 96: 9827-9832.
30. Skinner M, Qu S, Moore C, Wisdom R. Transcriptional activation and transformation by FosB protein require phosphorylation of the carboxyl-terminal activation domain. Mol Cell Biol 1997; 17: 2372-2380.
31. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG. Chemosensitivity linked to p73 function. Cancer Cell 2003; 3: 403-410.
32. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M et al. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 2004; 279: 41504-41511.
33. Lin Y, Martin J, Gruendler C, Farley J, Meng X, Li BY et al. A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol 2002; 3: 15.
34. Lim SK, Gopalan G. Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene 2007; 26: 6593-6603.
35. Kasbek C, Yang CH, Fisk HA. Antizyme restrains centrosome amplification by regulating the accumulation of Mps1 at centrosomes. Mol Biol Cell 2010; 21: 3878-3889.
36. Yuan Q, Ray RM, Viar MJ, Johnson LR. Polyamine regulation of ornithine decarboxylase and its antizyme in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2001; 280: G130-G138.
37. Seiler N, Renault J, Gossé F, Roussi S, Raul F. Cytotoxicity of the polyamine oxidase inactivator MDL 72527 to cancer cells: comparison with a saturated structural analogue. Int J Oncol 2005; 27: 1669-1676.
38. Wang X, Feith DJ, Welsh P, Coleman CS, Lopez C, Woster PM et al. Studies of the mechanism by which increased spermidine/spermine N1-acetyltransferase activity increases susceptibility to skin carcinogenesis. Carcinogenesis 2007; 28: 2404-2411.
39. Chen Y, Megosh LC, Gilmour SK, Sawicki JA, O'Brien TG. K6/ODC transgenic mice as a sensitive model for carcinogen identification. Toxicol Lett 2000; 116: 27-35.
40. Nowotarski SL, Woster PM, Casero Jr RA. Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 2013; 15: e3.
41. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 1999; 21: 326-329.
42. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E136; Review.
43. Hazzalin CA, Le Panse R, Cano E, Mahadevan LC. Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol Cell Biol 1998; 18: 1844-1854.
44. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003; 4: 879-889.
45. Toft DJ, Rosenberg SB, Bergers G, Volpert O, Linzer DI. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc Natl Acad Sci USA 2001; 98: 13055-13059.
46. Baumann S, Hess J, Eichhorst ST, Krueger A, Angel P, Krammer PH et al. An unexpected role for FosB in activation-induced cell death of T cells. Oncogene 2003; 22: 1333-1339.
47. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004; 279: 44713-44722.
48. Igarashi K, Kashiwagi K, Hamasaki H, Miura A, Kakegawa T, Hirose S et al. Formation of a compensatory polyamine by Escherichia coli polyamine-requiring mutants during growth in the absence of polyamines. J Bacteriol 1986; 166: 128-134.